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Primary biliary cirrhosis (PBC) is a chronic liver disease of
unknown etiology predominantly affecting females. It is
characterized by inflammation and destruction of the intra-
hepatic biliary ducts and it leads to the development of
chronic cholestasis. The clinical manifestations are similar to
those of cirrhosis, including pruritus, jaundice, xanthomas,
steatorrhea and malabsorption [1].
The disease generally affects women between 40 to 60
years of age. The age at the time of diagnosis, however, is
decreasing with diagnosis being achieved earlier and in
asymptomatic patients. The reason for the female predomi-
nance of 90% is unknown [2]. Primary biliary cirrhosis has
been reported throughout the world. The prevalence in
Western Europe is 22 cases per one million inhabitants, al-
though this may vary from country to country and within a
country. Although familial cases have been reported, there
is no epidemiologic evidence that the disease is hereditary
or limited to certain social or ethnic groups [3].
Scheuer classified PBC into 4 stages from a morphologic
point of view [4]. In Stage I, a lesion characteristic of the bil-
iary ducts (granuloma) may be seen. In Stage II there is duc-
tal proliferation, hepatic fibrosis is observed in Stage III and
hepatic cirrhosis in Stage IV. The stages are usually pro-
gressive and, in some cases, lesions of one or two stages
may overlap. This histologic classification was later modified
by Ludwig et al, and lesions were redefined as portal, peri-
portal, septal and cirrhotic [5,6].
The initiation of the disease is variable. It may be acci-
dently found during a routine medical examination with the
observation of hepatomegaly or splenomegaly or on deter-
mining a marked increase in alkaline phosphatases or a
slight rise in transaminases (in the asymptomatic forms). On
other occasions, the initiation is insidious, similar to other
chronic liver diseases. In certain cases, the first clinical man-
ifestations are like those of autoimmune chronic hepatitis
and in other cases they are similar to hepatic cirrhosis. The
disease sometimes becomes manifest with pruritus and
jaundice in pregnancy or after the consumption of oral con-
traceptives. In most cases, the first symptom, is pruritus
which may precede the appearance of jaundice by months
or even years. The initial clinical manifestations vary in
length from one patient to another, until the manifestations of
the different stages are presented. Jaundice, xanthomas,
steatorrhea and malnutrition may also be observed.
The most common biochemical alteration of PBC is an in-
crease in all those substances normally eliminated by the
bile. Alkaline phosphatases are usually elevated, with the
levels increasing with the evolution of the disease [7,8].
Other cholestatic markers, such as 5’-nucleotidase and
gammaglutamyltransferase are also elevated. Bilirubin is
usually normal at initiation of PBC and increases on progres-
sion of the disease. The levels of bile acids and cholesterol
are usually elevated during the disease. These changes are
probably due to inhibition of the hepatic lipase disease in the
intitial stages and a decrease in the esterification of choles-
terol in the most advanced phases [9]. A slight elevation in
transaminases may be observed. Albumin and prothrombin
time are usually normal in the initial stages of the disease,
but may change with progression and the appearance of
signs of liver failure [7,8]. Moreover, hypergammaglobuline-
mia, erythrocyte sedimentation rate and normocytic and nor-
mochronic anemia may be observed. In 75% of the cases,
hypergammaglobulinema is a consequence of the marked
increase in immunoglobulin M. Immunoglobulin G is also
usually increased, while immunoglobulin A is usually normal.
One of the most important diagnostic tests is the determi-
nation of antimitochondrial antibodies (AMA) which are
found in 90 to 95% of the cases of PBC. The AMA are non
organospecific antibodies that react against a lipoproteidic
component of the internal membrane of the mitochondria
[10]. To date, 9 types of AMA have been determined and it
has been demonstrated that they may be associated with
several diseases, some of which are specific. Patients with
PBC react with the M2, M4, M8 and M9 subtypes, with the
most frequent in PBC being the M2 subtypes [11]. In addi-
tion to AMA, other non organospecific circulating antibodies,
such as antinuclear [12], antithyroid and anti smooth muscle
antibodies [13] may be observed.
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Treatment of PBC
Treatment of PBC is directed at improving, or preventing, the
effects of chronic cholestasis and reversing the mechanism
or mechanisms determining its appearance by specific
treatment.
Symptomatic treatment
Patients may carry out normal physical activity while their
general state allows them to do so. No special diet is re-
quired, as long as correct protein and calory intake is main-
tained. Moderate sunbathing is convenient and at least half
a liter of milk should be ingested daily to counterbalance the
deficit of intestinal vitamin D and calcium absorption. Only
alcohol intake is contra-indicated.
Treatment of pruritis
Pruritus is one of the most bothersome symptoms in PBC.
Many therapeutic measures have been used, among which
the administration of cholestyramine and phenobarbitone
are the most well known.
Cholestyramine is a resin of ionic exchange which
is bound to the bile salts in the intestinal lumen impeding
their absorption. It is administered orally at an intitial dose
of 12 g 3 times a day [14-17], with administration at break-
fast being double that of the posterior dose since the biliary
vesicle is full of bile in the morning. It is therefore recom-
mended that the dosage be divided as 4 g before break-
fast, 4 g after breakfast and the remaining 4 g before to
lunch. A reduction in pruritus is not usually observed for
about 3 days, when the reservoir of bile salts has de-
creased. Cholestyramine may cause constipation and in-
testinal discomfort. In cases in which cholestyramine is not
effective at the dosis indicated, an increase in dosage is
not useful.
Phenobarbitone is a powerful enzyme inducer and
cholerectic which increases bile flow, regardless of the bile
salts. It is usually administered at an initial dose of 3 mg/kg
of b.w. over the first 4 days, and is thereafter reduced to 50-
100 mg/day in only one nightly dose. Prolonged phenobarbi-
tone administration may produce somnolescence and alter
vitamin D metabolism.
Rifampicin is an antibiotic with an intense induction ca-
pacity on the hepatic microsomal system. It significantly re-
duces pruritus and is much more effective than phenobarbi-
tone [18-21]. In addition, it is accompanied by a marked
decrease in alkaline phosphatase levels, transaminases
and even, despite the enzymatic induction effect, by a de-
crease in gammaglutamyltransferase. Rifampicin may be
administered over long periods with a certain amount of
safety, although the transaminase levels should be monitor-
ized for hepatotoxicity, which occurs in about 15% of the
cases.
Other substances used against pruritus in PBC are opiate
antagonists [22,23] (naloxone, namelfen, naltrexone), pro-
pofol [24] and S-adenosylmethionine [25].
Treatment of malabsorption
Due to a lack of bile acids in the intestinal lumen, malabsorp-
tion of liposoluble vitamins is observed. To avoid these defi-
ciences, vitamin D should be administered as 25-hydroxyc-
holecalciferol at a dose of 266 g every 8-15 days. Calcium
supplements such as calcium gluconate are given orally at 3
g/day, representing 1500 mg of calcium element/day [26].
Vitamin A is administered at a dose of 50,000 IU every 15
days to avoid hemeralopia or night blindness [27]. Vitamin K
may be administered intramuscularly (10 mg every week) if
the prothrombin time is decreased. Vitamin E is given orally
at 200 mg/day to improve asthenia [28]. In some malnour-
ished patients, medium chain triglycerides are recommend-
ed such as coconut oil extract at one soup spoon 3 or 4
times a day.
Treatment of osteodystrophy
Osteodystrophy is frequent in PBC patients, consisting of
the combination of a progressive reduction in bone volume
(osteoporosis) and a bone mineralization deficit (osteomala-
cia) [29]. The previously mentioned administration of vitamin
D and calcium at the doses indicated does not always pre-
vent the appearance of osteoporosis [30]. Since osteoporo-
sis is fundamentally produced as a consequence of defi-
cient osteoblastic function, sodium fluoride [31] has been
studied in these patients with good results and has been
found to prevent a decrease in bone mass. At present, other
antireabsorption therapies such as calcitonine and dephos-
phonates are being studied.
Treatment of hyperlipidemia
There is currently no adequate treatment against hyper-
lipemia in PBC. In cases with intense neuritic pain by xan-
thomatous invasion of the nerve lining, plasmapheresis with
activated charcoal is recommended.
Specific treatment
Several specific therapies for PBC have been studied. These
treatments are usually divided into 2 groups; immunomodu-
lators, such as corticoids, azathioprine, cyclosporin and
methotrexate and other drugs which, in addition to their anti-
inflammatory action, produce an antifibrogenetic effect,
such as penicillamine and colchicine. The other group only
includes ursodeoxycholic acid, the beneficial effect of which
is due to a decrease in toxic bile acids.
Corticoids
Corticoids have an immunosuppressive effect and were first
administered in 1955. In this study, promising beneficial clin-
ical and biochemical data were demonstrated but with the
disadvantage of a clear exacerbation of the metabolic bone
disease. In later studies [32], similar results were observed,
even with the addition of oral calcium and vitamin D supple-
ments. That is, improvement was observed in biochemical
and some histologic parameters, but with a decrease in
bone trabecular volume by densitometry and seried bone
biopsies. Nonetheless, the controversy regarding its use is
not as yet resolved and the results of a recent study appear
to justify the indication of low dose corticoids [33]. Patients
with PBC receiving a dose of prednisolone of 10 mg/day
over 3 years did not show any significant differences in bone
mineral content versus the control group. However, although
analytical and histologic improvement was observed with
corticoids, no changes were reported with respect to sur-
vival in the 2 groups.
Further information is required regarding the usefulness
of second generation synthetic corticoids, such as budes-
onide, which has a 15-fold greater affinity for the glucocorti-
coid receptor. Corticoids are well absorbed in the intestine
and up to 90% of the oral dose is metabolized in the liver,
minimizing the secondary effects which are systemically un-
desirable. Another third generation synthetic corticoid which
may be useful is deflazacort. However, insufficient informa-
tion is available concerning its possible usefulness in PBC.
Azathioprine
Initial studies indicated that azathioprine was not effective in
the treatment of PBC. In later analysis of the latest controlled
trial, azathioprine was found to have a small beneficial effect
on very slightly improving the survival of PBC patients [34].
This effect, however, was so small that azathioprine proba-
bly has no efficacy.
Penicillamine
Penicillamine was used after azathioprine. In addition to be-
ing a copper chelate, penicillamine has an immunosuppres-
sive and antifibrogenetic effect. Its use, however, did not
demonstrate any beneficial effect, but did produce numer-
ous secondary effects, some of which were severe [35].
Colchicine
The use of colchicine in PBC was justified by its antiinflam-
matory and antifibrogenetic properties. The dosage of
colchicine used is 1.2 mg/day. It causes a reduction in para-
meters of cytolysis and cholestasis, hyperbilirubinemia and
cholesterol, increasing serum albumin. Likewise, the mortal-
ity was significantly lower in patients treated than in controls
receiving placebo [36]. Despite this clear therapeutic effica-
cy, a long term follow up study did not show any evident im-
provement in the prognosis of these patients [37].
Nonetheless, no histologic improvement was observed.
Further controlled studies are currently required, including a
larger number of patients in order to confirm the effective-
ness of colchicine in PBC.
Cyclosporine
Cyclosporine A is a powerful immunosuppressive drug that
was initially studied in few patients with PBC. Although pruri-
tus and biochemical alterations improved in the patients
treated, no clear histologic evidence was found [38].
Cyclosporine A does not appear either to increase the sur-
vival or prevent the complications of PBC, which, together
with its nephrotoxic and hypertensive effects, has led to its
discontinuation in more extensive studies. In a more recent
study, in patients with PBC, cyclosporine A increased the
biochemical parameters of bone remodelling and impeded
the loss of bone mass. However, in an extensive multicenter
European study [39], including 349 patients, cyclosporine A
was not found to improve the survival of PBC patients.
Methotrexate
The use of methotrexate at a dose of 15 mg/week over 12
months produced an improvement in clinical manifestations,
biochemical parameters and hepatic inflammation [40].
Nonetheless, long term treatment is uncertain because of
possible severe secondary effects such as myelosuppres-
sion, hepatotoxicity or interstitial pneumopathy. Further
studies are required to confirm these hopeful initial studies.
Ursodeoxycholic acid
Ursodeoxycholic acid (UDCA) increases the intrahepatic
content of the hydrophillic bile acids, but decreases hy-
drophobic bile acids (cholic and lithocholic) which induce a
hepatotoxic effect [41]. Apart from this main activity, other
mechanisms of additional action are attributed to UDCA [42-
46]: 1) it inhibits the intestinal absorption of endogenous bile
acids; 2) it produces choleresis rich in bicarbonate; 3) it has
a hepatoprotector effect, stabilizing the hepatocellular mem-
brane; 4) it inhibits the expression of class I HLA antigens in
the hepatocytes, impeding the cytotoxicity measured by T-
lymphocytes, and 5) it has the capacity of developing im-
munomodulatory effects.
In the first pilot study in 1987, it was observed that UDCA
reduced pruritus and was accompanied by a marked de-
crease in alkaline phosphatases and transaminases with few
undesirable secondary effects, which were found to disap-
pear on discontinuation of treatment [47]. These results led
to the initiation of many controlled clinical trials. The data ob-
tained in wide prospective studies demonstrated that UDCA
is safe and well tolerated, achieving a clear improvement in
biochemical parameters. The results of one multicenter
study [48] confirmed the effectiveness of a dose of 13-15
mg/day of UDCA versus placebo in patients with PBC,
demonstrating a significant improvement in serum bilirubin
levels, alkaline phosphatases, gammaglutamyltransferase,
cholesterol and immunoglobulin M. Morevoer the patients
who were treated with UDCA also showed a significant de-
crease in the index of histologic activity, with the exception
of fibrosis, which did not vary. Recent long term studies [49-
52] suggest that sustained treatment with UDCA reduces
the progression to the histologic lesions of PBC, prolongs
patient survival or delays the indications for liver transplanta-
tion. The results of long term treatment with UDCA amplify
the information of the intitial study [51]. In this study all the
patients who had received placebo for 2 years were treated
with the same dose of UDCA for another 2 years and the re-
maining patients received UDCA for 4 years. The disease
progressed more slowly in those who received UDCA than in
those who had received placebo. The probability of fulfilling
criteria for liver transplantation or mortality was significantly
lower in patients treated with UDCA than in those who re-
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ceived placebo during the first 2 years. Treatment with
UDCA was found to be ineffective, particularly in patients
with high levels of bilirubin, and total bile acids, and low
serum albumin concentration, as well as the presence of he-
patomegaly and splenomegaly.
The results of a meta-analysis published based on the effec-
tiveness of UDCA in PBC confirm the therapeutic value of this
acid since an improvement was observed in the analytical and
histological parameters and because the incidence of treat-
ment failure was very low [53]. This study analyzed 5 clinical se-
ries and 7 controlled studies of patients with PBC treated with
UDCA. All the trials showed a favorable effect of the treatment
in transaminases, alkaline phosphatases and gammaglu-
tamyltransferase levels, but the results in bilirubin were not ho-
mogeneous. Five of the 12 studies evaluated the effect of
UDCA on histology with variable results. In 2, histologic im-
provement was observed, while in another 2, the changes were
not significant and in the remaining study histologic deteriora-
tion was observed. The global analysis of these studies, how-
ever, concluded that UDCA has favorable histologic effects.
The results of 2 studies [54,55] showed improvement in
the survival of PBC patients treated with UDCA. The first
study was a meta-analysis based on 3 studies including a
total of 553 patients with a mean follow up of 4 years. The
other study was based on the follow up of 180 patients over
4 years. The results of these studies indicate that the pa-
tients treated with UDCA versus a placebo group, presented
a significantly longer survival, in addition to a lower inci-
dence of liver transplantation.
On the other hand, a multicenter, randomized, double-
blind, study has recently been concluded in Spain [56] with
the aim of investigating the effect of UDCA in PBC. In this
study, no improvement was seen in survival, although an im-
provement was observed in the biochemical parameters of
cholestasis and cytolysis as well as in histologic lesions.
Despite these hopeful results, other studies have demon-
strated disease progression in patients treated with UDCA
[57,58]. Therefore, in the future, the characteristics of the
PBC patients who may benefit from treatment with UDCA
should be established. From the data currently available,
however, it appears that the best results have been
achieved in patients in whom the disease has evolved little
and who would have the greatest probability of reversal.
Likewise, the asymptomatic patients may benefit from this
treatment with the greatest guarantees of success, since
prolonged UDCA treatment is not accompanied by impor-
tant secondary effects and is well tolerated.
We can therefore conclude that from the present data,
most PBC patients should be treated with UDCA at doses
ranging from 13-15 mg/kg/day, with the exception of those
patients with advanced disease who are candidates for liver
transplantation, since the results in this group of subjects are
not favorable.
Liver transplant
When cholestasis progresses, despite the previous thera-
peutic maneuvers, the only treatment possible is liver trans-
plant. The problem in these cases is to determine the time of
transplant, although most groups agree that the variables
determining transplant are the levels of hyperbilirubinemia
and the manifestations secondary to portal hypertension
[59]. In fact, the patients with PBC with a grim prognosis, low
quality of life, or both, are particularly appropriate for trans-
plantation. It is a safe and effective therapeutic option in the
advanced stages of the disease when untreatable malnutri-
tion, pruritus or osteodystrophy or bilirubin greater than 6
mg/dl are observed. Other factors to take into account at the
time of deciding transplantation are the presence of refrac-
tory ascites, bleeding from rupture of esophageal varices,
spontaneous bacterial peritonitis, hepatorenal syndrome,
recurrent biliary sepsis, hepatic encephalopathy or the pres-
ence of hepatocarcinoma.
The survival of PBC patients at one year following liver
transplanation is greater than 70%, and more than 80% of
the survivors achieve complete professional and social ac-
tivity [60,61]. Furthermore, the survival at 5 years is greater
than 75% [62].
Following liver transplantation the patients present a rapid
improvement in the symptoms and complications of the dis-
ease, such as in pruritus, jaundice, encephalopathy or
esophogeal varices. Unfortunately, despite treatment with
calcium and vitamin D, an initial worsening is observed in
osteoporosis and osteomalacia [63]. This may be related to
the inactivity and the corticosteroids and other immunosup-
pressive therapies. Bone disease improves in prolonged
survival.
The possibility of disease recurrence in the transplanted
liver has been suggested [64,65], due to the reappearance
of some antimitochondrial antibodies titers shortly after liver
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Vitamin A 50,000 IU/15 days, orally
Vitamin K 10 mg/week, i.m.
Vitamin E 200 mg/day, orally
Vitamin D 266 g/8-15 days, orally
Calcium gluconate 3 g/day, orally
Medium chain triglycerides 20 mg/8 hours
Table 1. Treatment of nutritional deficiencies in primary biliary cir-
rhosis.
Hyperbilirubinemia greater than 6 mg/dl
Child Pugh Grade B or C hepatic dysfunction
Bleeding by rupture of esophageal varices in Child Pugh
Grade B or C
Untreatable pruritus or invalidating asthenia





Criteria of parenchymatous liver diseases
Table 2. Criteria for indication of liver transplantation in patients
with primary biliary cirrhosis.
transplantation., However, it is currently difficult to distin-
guish recurrence from chronic graft rejection. Both process-
es demonstrate nonsuppurative cholangitis with weakness
of the biliary tract. Nevertheless, patients with PBC have a
greater incidence of chronic rejection caused by graft failure
than other patients submitted to liver transplantation.
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